PRINCETON, NJ -- (MARKET WIRE) -- 03/15/2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that it acquired the exclusive rights to market and distribute Denavir® (penciclovir cream) 1% in Canada from Novartis Consumer Health, Inc., an affiliate of Novartis, Inc. Denavir is a topical antiviral prescription medication indicated for the treatment of herpes labialis, also known as cold sores, in adults. This is the only topical antiviral prescription product approved by Health Canada for treating this condition. Under the terms of the agreement, Barrier will be the exclusive distributor of Denavir in Canada and will be responsible for all sales, marketing and distribution activities. Novartis Consumer Health will be responsible for supplying Barrier with finished goods.
